103 related articles for article (PubMed ID: 27496408)
1. Prostate-Specific Antigen: Nonspecific in Deceased Organ Donors.
Pabisiak K; Ostrowski M; Kram A; Safranow K; Myślak M; Sieńko J; Sulikowski T; Ciechanowski K
Transplant Proc; 2016 Jun; 48(5):1374-7. PubMed ID: 27496408
[TBL] [Abstract][Full Text] [Related]
2. Prostate Specific Antigen-Positive Deceased Organ Donor: A Pathologist Is Indispensable.
Pabisiak K; Ostrowski M; Kram A; Safranow K; Słojewski M; Ciechanowski K
Transplant Proc; 2016 Sep; 48(7):2450-2453. PubMed ID: 27742319
[TBL] [Abstract][Full Text] [Related]
3. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
Tarle M; Kraljić I
Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen density: the role in benign prostate hyperplasia, prostate intraepithelial neoplasm, organ-confined prostate carcinoma and advanced prostate carcinoma.
Işikay L; Yaman O ; Bozlu M; Müftüğlu YZ; Göğüş O
Int Urol Nephrol; 1995; 27(6):757-61. PubMed ID: 8725043
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen: insufficient discrimination between benign prostatic hyperplasia and organ-confined prostate cancer.
Wolff JM; Boeckmann W; Borchers H; Handt S; Reineke T; Jakse G
Urol Int; 1996; 57(3):170-4. PubMed ID: 8912446
[TBL] [Abstract][Full Text] [Related]
6. Prostate tissue and serum markers.
Mazzucchelli R; Colanzi P; Pomante R; Muzzonigro G; Montironi R
Adv Clin Path; 2000 Jul; 4(3):111-20. PubMed ID: 11080790
[TBL] [Abstract][Full Text] [Related]
7. Optimum PSA reflex-range.
Benecchi L
Arch Ital Urol Androl; 2006 Jun; 78(2):44-8. PubMed ID: 16929601
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen density values among patients with symptomatic prostatic enlargement in Nigeria.
Udeh EI; Nnabugwu II; Ozoemena FO; Ugwumba FO; Aderibigbe AS; Ohayi SR; Echetabu KN
World J Surg Oncol; 2016 Jun; 14(1):174. PubMed ID: 27356753
[TBL] [Abstract][Full Text] [Related]
9. [BIOMARKERS OF EARLY AND DIFFERENTIAL DIAGNOSIS OF PROSTATIC CANCER].
Grygorenko VM; Danylets RO; Vikarchuk MV; Gorbahn LV; Klepko AV
Klin Khir; 2017; (1):54-7. PubMed ID: 30272918
[TBL] [Abstract][Full Text] [Related]
10. The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer.
Fowke JH; Motley SS; Barocas DA; Cookson MS; Concepcion R; Byerly S; Smith JA
Cancer Causes Control; 2011 Mar; 22(3):417-26. PubMed ID: 21170754
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment Serum Cystatin C Levels Predict Renal Function, but Not Tumor Characteristics, in Patients with Prostate Neoplasia.
Yang F; Li D; Di Y; Zhang Y; Zang Y; Ren J; Yan L; Zhou Z; Liu H; Xu Z
Biomed Res Int; 2017; 2017():7450459. PubMed ID: 28812020
[TBL] [Abstract][Full Text] [Related]
12. Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma?
Raviv G; Zlotta AR; Janssen Th; Descamps F; Vanegas JP; Verhest A; Schulman CC
Cancer; 1996 May; 77(10):2103-8. PubMed ID: 8640677
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of total and percent free prostate specific antigen in high grade prostatic intraepithelial neoplasia lesions: results of the Tyrol Prostate Specific Antigen Screening Project.
Horninger W; Volgger H; Rogatsch H; Strohmeyer D; Steiner H; Hobisch A; Klocker H; Bartsch G
J Urol; 2001 Apr; 165(4):1143-5. PubMed ID: 11257656
[TBL] [Abstract][Full Text] [Related]
14. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
[TBL] [Abstract][Full Text] [Related]
15. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
16. Cytokeratin 8/18 levels in patients with prostate cancer and benign prostatic hyperplasia.
Wolff JM; Borchers H; Brehmer B; Brauers A; Jakse G
Urol Int; 1998; 60(3):152-5. PubMed ID: 9644784
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen as tumor marker: relationship with histologic grading.
Xess A; Singh M; Raghwendra KH; Sharma HP; Shahi SK
Indian J Pathol Microbiol; 2001 Jul; 44(3):261-4. PubMed ID: 12024909
[TBL] [Abstract][Full Text] [Related]
18. [Significance of the PSA-concentration for the detection of prostate cancer].
Stachon A
Pathologe; 2005 Nov; 26(6):469-72. PubMed ID: 16195861
[TBL] [Abstract][Full Text] [Related]
19. Importance of tumoral markers in donors: study of prostate-specific antigen.
González-Segura C; Pascual M; Cañizares R; García-Huete L; Torras J; Riera L; Condom E
Transplant Proc; 2003 Aug; 35(5):1647-9. PubMed ID: 12962743
[TBL] [Abstract][Full Text] [Related]
20. [Contribution of PSA and its density in the diagnosis and tracking of the prostate cancer].
Yousra S; Rafik E; Manel M; Kacem M
Ann Biol Clin (Paris); 2010; 68(5):585-93. PubMed ID: 20870581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
